阿美替尼、安罗替尼靶向治疗非小细胞肺癌的前瞻性研究
A prospective study on targeted therapies of non-small cell lung cancer using almonertinib or anlotinib
陈文丽 1吴新龙 2卢彪2
作者信息
- 1. 修水县中医院药剂科,江西 九江 332400
- 2. 修水县中医院肿瘤科,江西 九江 332400
- 折叠
摘要
目的:探究阿美替尼、安罗替尼靶向治疗非小细胞肺癌(Non-small cell lung carcinoma,NSCLC)的前瞻性对照研究.方法:将 2020 年 1 月至 2023 年 6 月在本院接受治疗的 92 例非小细胞肺癌患者作为研究对象,随机分为阿美替尼组和安罗替尼组,每组 46 例.阿美替尼组接受阿美替尼治疗,安罗替尼组接受安罗替尼治疗.比较两组治疗前后免疫指标、炎症因子水平、疗效和两组不良反应发生率.结果:治疗后阿美替尼组成熟T淋巴细胞和自然杀伤细胞的水平均高于安罗替尼组(P＜0.05);治疗后阿美替尼组的超敏C反应蛋白、白介素-6、白介素-8 水平均低于安罗替尼组(P＜0.05).结论:阿美替尼治疗NSCLC效果优于安罗替尼,改善患者体内免疫指标、炎症因子的水平.
Abstract
Objective:To study the therapeutic effect of targeted therapies with almonertinib or anlotinib on non-small cell lung cancer(NSCLC).Methods:A total of 92 patients with NSCLC treated in our hospital from January 2020 to June 2023 were selected as the study subjects,and randomly divided into the almonertinib group and the anlotinib group,with 46 patients in each group.The almonertinib group was treated with almonertinib,while the anlotinib group was treated with anlotinib.The immune indicators,levels of inflammatory factors,therapeutic effect,and incidence of adverse reactions were compared between the two groups.Results:After treatment,the levels of mature T lymphocytes and natural killer cells in the almonertinib group were higher than those in the anlotinib group(P<0.05).The levels of high-sensitivity C-reactive protein,interleukin-6 and interleukin-8 in the almonertinib group were lower than those in the anlotinib group(P<0.05).Conclusion:Almonertinib is more effective than anlotinib in the treatment of NSCLC.It can improve the levels of immune indicators and inflammatory factors.
关键词
非小细胞肺癌/阿美替尼/安罗替尼/对照研究Key words
Non-small cell lung cancer/Almonertinib/Anlotinib/Controlled study引用本文复制引用
出版年
2024
NETL
NSTL
维普
万方数据